New partnership to develop schizophrenia treatments New partnership to develop schizophrenia treatments Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
New spesolimab data show significant improvement in GPP flares New spesolimab data show significant improvement in GPP flares New spesolimab data show significant improvement in GPP flares
Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
discontinuation-bi-1467335-diabetic-retinopathy discontinuation-bi-1467335-diabetic-retinopathy The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
new_analysis_nintedanib_SSc_ILD new_analysis_nintedanib_SSc_ILD Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Phase II results cognitive impairment schizophrenia Phase II results cognitive impairment schizophrenia Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
Geographic Atrophy treatment to move to Phase II Geographic Atrophy treatment to move to Phase II Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
Spesolimab Phase II data Spesolimab Phase II data New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
Breakthrough Phase 2 survodutide data liver fibrosis MASH Breakthrough Phase 2 survodutide data liver fibrosis MASH Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis